Record Details     « Return to search results       Brief Record Full Record MARC Record     Bibliographic Data Control Number 370203 Date and Time of Latest Transaction 20201212060927.AM General Information 201212s |||||||||b ||00||| Cataloging Source DOST-PCHRD Main Entry - Personal Name Evangelista, Karen V Title Statement "Detection of Hepatitis B Virus (HBV) infection among apparently healthy adults undergoing pre-employment screening: A Comparison Between Three Hepatitis B markers: HBV DMA, HBsAg and anti-HBc" Physical Description 0 Summary, Etc. The prevention of transfusion-transmitted Hepatitis B virus (HBV) in the country has relied solely on serological screening of blood donors using Hepatitis B surface antigen (HBsAg) using either enzyme immunoassay or dipstick method. However, studies have shown that HBV infection may be missed out by these assays for HBsAg if the infected person is within the immunological window period in which HBsAg is undetectable. This study determined if the addition of other HBV serological markers -the antibody to Hepatitis B core antigen (anti-HBc) and HBV DNA (using pooled serum samples) - could represent an alternative in detecting the presence of the virus. A prospective study of 315 serum samples from apparently healthy adults was conducted to determine the prevalence of HBV infection using the three different HBV markers and combination of these marke'rs. The presence of HBsAg in the sera of apparently healthy individuals was detected using Hexagon HBsAg test (Human, Germany). The prevalence using this immunochromatographic method was compared to an enzyme immunoassay carried out as part of the pre-employment screening using MONOLISA Ag HBs PLUS (Bio-Rad Laboratories, France) also detecting the presence of HBsAg. The Igm antibodies to hepatitis B virus core antigen was detected in the sera of healthy adults using enzyme immunoassay using ImmunoLISA HBc Igm kit (Orgenics, Israel). HBV DNA was quantitatively detected using Amplicor HBV Monitor Test (Roche Diagnostics, Mannheim, Germany) using pooled serum samples. HBsAg was detected in 3.8 percent apparently healthy individuals, a rate lower than the prevalence of the general population in the Philippines published in the 1980s. Anti-HBc marker was observed in 0.95 percent of the subjects. The use of anti-HBc marker in addition to HBsAg has detected two more individuals with HBV, increasing the prevalence of HBV infection from 3.8 percent to 4.4 percent. HBV DNA was carried out in minipools of sera, a routine practice among laboratories performing nucleic acid testing. Out of the 32 pools, 22 were HBV DNA-positive. Assuming that one individual in each pool contributed to its positivity, then 6.98 percent of the subjects were HBV DNA-positive. All HBsAg-positive sera were found to be also positive for HBV DNA. The combined HBV markers to detect the presence of HBV have resulted to a higher rate of detection rate for HBV infection (7.30 percent). The use of HBsAg alone as a screening marker is inferior to using a combination of two markers: HBsAg and anti-HBc. Nucleic acid testing when used alone with minipool of blood samples, was the best method for the detection of HBV infection. Future investigations should focus on the feasibility of adapting an improved screening strategy in the Philippines that incorporates the use of a combination of HBsAg and anti-HBc or HBV DNA in routine blood testing Subject Added Entry - Topical Term HEPATITIS B   HEPATITIS B VIRUS   ADULT   PROSPECTIVE STUDIES   PREVALENCE   HEPATITIS B SURFACE ANTIGENS   HEPATITIS B VIRUS INFECTION   HBV   PRE-EMPLOYMENT SCREENING   HBV DNA   HBSAG   ANTI-HBC   HEPATITIS B   HEPATITIS B VIRUS   ADULT   PROSPECTIVE STUDIES   PREVALENCE   HEPATITIS B SURFACE ANTIGENS           Physical Location           Digital Copy Not Available          Add to Book Cart  |   Download MARC